RR

Rahul Rajendren Santhakumari

Active Director Designated Partner DIN 10889149
DIN 10889149 First appointment Dec 2024 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Dec 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Rahul Rajendren Santhakumari

Data last updated:

Rahul Rajendren Santhakumari is a Designated Partner at Qbycare Pharmaceuticals Llp (since 2024). The company operates in Pharma.

DIN 10889149
Primary Designation Designated Partner
Industry Pharma
First Appointment 27 Dec 2024
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner27 Dec 20242024Active

Board colleagues of Rahul Rajendren Santhakumari

NameDINCompanyDesignation
Muthiruthiparambil Raju Vishnu Raj10889148Qbycare Pharmaceuticals LlpDesignated Partner

Directorship timeline

Open interactive timeline →
Qbycare Pharmaceuticals Llp
Premium access

Shareholding and investment profile for Rahul Rajendren Santhakumari

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rahul Rajendren Santhakumari

Rahul Rajendren Santhakumari currently holds 1 directorship: Qbycare Pharmaceuticals Llp (Designated Partner, since 27 Dec 2024).

Rahul Rajendren Santhakumari was first appointed on 27 Dec 2024 as Designated Partner at Qbycare Pharmaceuticals Llp.

The current boards of Rahul Rajendren Santhakumari's companies include Muthiruthiparambil Raju Vishnu Raj (Qbycare Pharmaceuticals Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available